Navigation Links
Smile: Gingivitis bacteria manipulate your immune system so they can thrive in your gums
Date:1/3/2013

A new research report published in the Journal of Leukocyte Biology shows how the bacteria known for causing gum disease--Porphyromonas gingivalis--manipulates the body's immune system to disable normal processes that would otherwise destroy it. Specifically, the report shows that this pathogen prompts the production of the anti-inflammatory molecule Interleukin-10 (IL-10). This, in turn, inhibits the function of T-cells, which would otherwise help to protect the host from this particular microbial infection.

"Since greater than 50 percent of the U.S. population over 50 years-of-age develop adult periodontal disease, we hope that the results of our study will ultimately help in the development of novel treatments that could prevent or ameliorate the chronic infection caused by the pathogen P. gingivalis,'" said Jannet Katz, D.D.S., Ph.D., a researcher involved in the work from the Department of Pediatric Dentistry at the University of Alabama in Birmingham.

To make this discovery, scientists used cells from mice that were exposed to P. gingivalis. One portion of the cells was treated with an inhibiting antibody against IL-10 and the other portion of cells was not treated. All of the cells were then tested for interferon gamma production. An increase of interferon gamma production was seen in the treated cells, but no increase was found in the untreated cells. These findings suggest that the damage done by P. gingivalis happens when the immune cells of the host are first exposed to this pathogen, and further implies that for treatment to be successful, it must be started as early as possible. This study highlights the mechanism by which P. gingivalis can establish a chronic infection in the form of periodontal disease and provides insight into how the disease develops. Results also demonstrate the importance of very early intervention either by eradication of the bacterium with specifically designed therapeutics or by prevention via the development of an effective vaccine.

"Gum diseases and the infections that cause them can be incredibly stubborn and difficult to treat," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "What isn't as well known is why these infections are so difficult to eradicate. These new studies now demonstrate that these bacteria go beyond merely evading our body's defenses and actually manipulate our immune systems for their own survival."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Leading evolutionary scientist to discuss how genome of bacteria has evolved
2. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
3. Team discovers how bacteria resist a Trojan horse antibiotic
4. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
5. Bacterial shock to recapture essential phosphate
6. Disarming disease-causing bacteria
7. Study shows unified process of evolution in bacteria and sexual eukaryotes
8. Invisible helpers: How probiotic bacteria protect against inflammatory bowel diseases
9. Researchers develop rapid test strips for bacterial contamination in swimming water
10. Bacteria discovery could lead to antibiotics alternatives
11. Agricultural bacteria: Blowing in the wind
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... , Nov. 17, 2016  AIC announces that it has just released a new ... that require high-performance scale-out plus high speed data transfer storage solutions. Photo ... ... ... Setting up a high performance computing ...
(Date:11/15/2016)... Nov 15, 2016 Research and Markets has ... to 2021" report to their offering. ... ... Billion by 2021 from USD 6.21 Billion in 2016, growing at ... Growth of the bioinformatics market is driven by the growing demand ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation of ... lumbar disc production, company President, Jake Lubinski will be traveling to Germany on ... disc in Cologne and Karlsruhe to discuss the benefits of a viscoelastic total ...
(Date:12/5/2016)... WOODCLIFF LAKE, N.J. , Dec. 5, 2016 ... its Phase 3 open-label two-year study of rufinamide, ... of the American Epilepsy Society (AES) held from ... . Analysis of final two-year safety, tolerability and ... therapy with rufinamide experienced similar safety and tolerability ...
(Date:12/4/2016)... DIEGO , Dec. 3, 2016  In five ... of Hematology (ASH) Annual Meeting and Exposition in ... biomedical engineering methods to improve the delivery of life-saving ... These new methods are designed to carry therapies directly ... needed most, which could provide a substantial advantage over ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
Breaking Biology Technology: